Physician profile
Martha H Hagaman
NPI 1700069861
$19,740.55
in general payments reported to CMS, 2019-2025
18 companies · $9,385 in 2025
The $9,385 reported for 2025 was more than what 95% of Sleep Medicine (Pediatrics) providers received nationally (typical 2025 total: $235).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $1,084 · 2021: $1,681 · 2022: $2,239 · 2023: $3,761 · 2024: $980 · 2025: $9,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,396 · Food and Beverage: $4,134 · Consulting Fee: $2,305 · Travel and Lodging: $1,206 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,396.00 |
| Food and Beverage | $4,134.35 |
| Consulting Fee | $2,304.50 |
| Travel and Lodging | $1,206.33 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $11,400.19 | 2019-2025 | Xywav, Xyrem |
| Harmony Biosciences LLC | $5,136.70 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals Lp | $749.46 | 2019-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $630.72 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $611.96 | 2022-2025 | Sunosi |
| Genentech, INC. | $276.33 | 2021-2024 | Xolair, Actemra |
| Regeneron Healthcare Solutions, INC. | $171.63 | 2022-2023 | Dupixent |
| Lilly USA, LLC | $163.77 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $155.41 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $119.63 | 2019 | |
| Zoll Respicardia, INC. | $89.86 | 2024-2025 | Remede System |
| Philips North America LLC | $86.01 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $60.89 | 2022-2025 | Quviviq |
| Resmed Corp | $25.82 | 2025 | |
| 3b Medical, INC. | $18.04 | 2023 | Luna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $17.40 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.24 | 2025 | Horizant |
| Apria Healthcare LLC | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Hagaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.